Sanofi-Aventis Takes Rights to Metabolex's Diabetes Compound
As it continues to diversify away from its juggernaut Lantus, Sanofi takes a chance on a potential first-in-class drug not yet through Phase II.
As it continues to diversify away from its juggernaut Lantus, Sanofi takes a chance on a potential first-in-class drug not yet through Phase II.